CN111329950A

CN111329950A - Application of traditional Chinese medicine composition and preparation thereof in preparation of medicine for treating acute lung injury

Info

Publication number: CN111329950A
Application number: CN202010220784.4A
Authority: CN
Inventors: 罗志毅; 洪绯; 袁慧君; 于娟; 林丽敏
Original assignee: Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Current assignee: Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority date: 2020-03-25
Filing date: 2020-03-25
Publication date: 2020-06-26

Abstract

The invention belongs to the field of traditional Chinese medicines, and particularly relates to application of a traditional Chinese medicine composition in preparation of a medicine for treating acute lung injury, wherein the traditional Chinese medicine composition comprises the following raw material medicines: rhizoma paridis, scutellaria baicalensis, thunberg fritillary bulb, dayflower, rhizoma anemarrhenae, gypsum, pericarpium citri reticulatae, fructus aurantii, cocklebur fruit, bitter almond, platycodon grandiflorum, pogostemon cablin, perilla leaf and honey-fried licorice root. Research results show that the traditional Chinese medicine composition can reduce the lung water content and the lung permeability index of rats with acute lung injury models, reduce the level of cell inflammatory factors, improve the pathological change of lung tissues of acute lung injuries, has obvious treatment effect on the acute lung injuries, and is suitable for clinical popularization and application.

Description

Application of traditional Chinese medicine composition and preparation thereof in preparation of medicine for treating acute lung injury

Technical Field

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition and application of a preparation thereof in preparation of a medicine for treating acute lung injury.

Background

Acute Lung Injury (ALI) is caused by injury of alveolar epithelial cells and capillary endothelial cells due to traumatic factors (such as sepsis, endotoxic shock, acute respiratory distress syndrome virus, aspiration pneumonia, contusion, pulmonary embolism and the like), and causes diffuse interstitial pulmonary and alveolar edema, clinically manifested as respiratory distress with symptoms of refractory hypoxemia, decreased lung compliance, and invasive diffuse inflammatory infiltration, and can directly transform into Acute Respiratory Distress Syndrome (ARDS) in severe cases. The morbidity is 79/10 ten thousand per year, and the mortality is 30-40%. At present, the clinical treatment means of acute lung injury mainly comprise two means of drug treatment and mechanical ventilation, and the use of a protective respirator treatment strategy can help a patient suffering from acute lung injury to a certain extent, but the death rate of the patient cannot be effectively reduced; drug therapy has some effect in controlling the disease, but there is no effective therapeutic drug at present.

For acute lung injury caused by bacterial infection, effective control of bacterial proliferation is a basic requirement of treatment, and active targeted treatment such as inhibition of inflammatory reaction and pulmonary edema is an important measure for promoting recovery of lung function on the basis of using antibacterial drugs such as antibiotics. The pathogenesis of acute lung injury has not been fully elucidated to date, where excessive deregulated inflammatory response and proinflammatory-anti-inflammatory response imbalance are thought to be the major pathogenesis of the disease, and complex network regulation between inflammatory cells and chemokines plays a major role in initiating, amplifying and promoting the pathological process. Therefore, the discovery of a drug for treating acute lung injury based on inflammatory response is of great significance. Corticosteroids can play a good anti-inflammatory role by inhibiting gene transcription of proinflammatory cytokines, inhibiting neutrophil activation, and the synergistic effect of anti-inflammatory molecules. At low to moderate doses [ 0.5-2.5 mg/(kg. d) ], corticosteroids increase gene transcription of anti-inflammatory molecules while inhibiting expression of pro-inflammatory mediators such as nuclear factor kappa B (NF-kB). At high doses [ 14-30 mg/(kg. d) ], corticosteroids act on cell surface receptors to promote non-genomic effects, such as membrane stabilization or inhibition of rapid neutrophil degranulation. High-dose administration of such drugs has been used to achieve non-genomic effects. However, a number of studies have shown that early treatment of ARDS patients with high doses of corticosteroids may increase mortality and cause adverse effects, and therefore such drugs are used for comprehensive assessment of acute lung injury.

With the research progress of the anti-inflammatory immune mechanism of the traditional Chinese medicine and the effective components thereof, more and more traditional Chinese medicines are applied to clinic, and the traditional Chinese medicines have the characteristics of lasting and mild effect, small side effect, remarkable improvement of clinical symptoms and the like, and better meet the treatment requirement of acute lung injury. Therefore, the research on the traditional Chinese medicine composition for treating acute lung injury has important significance.

Disclosure of Invention

Therefore, the technical problem to be solved by the invention is to provide a new application of a traditional Chinese medicine composition in preparing a medicine for treating acute lung injury.

Therefore, the invention provides the following technical scheme:

the application of a traditional Chinese medicine composition in preparing a medicine for treating acute lung injury comprises the following raw material medicines: rhizoma paridis, scutellaria baicalensis, thunberg fritillary bulb, dayflower, rhizoma anemarrhenae, gypsum, pericarpium citri reticulatae, fructus aurantii, cocklebur fruit, bitter almond, platycodon grandiflorum, pogostemon cablin, perilla leaf and honey-fried licorice root.

Preferably, the application of the traditional Chinese medicine composition in preparing the medicine for treating acute lung injury comprises the following raw material medicines in parts by weight:

100-160 parts of rhizoma paridis, 60-100 parts of scutellaria baicalensis, 100-160 parts of thunberg fritillary bulb, 250-300 parts of dayflower, 60-100 parts of rhizoma anemarrhenae, 150-200 parts of gypsum, 70-100 parts of dried orange peel, 60-100 parts of fructus aurantii, 100-150 parts of cocklebur fruit, 60-100 parts of bitter apricot seed, 60-100 parts of platycodon grandiflorum, 60-100 parts of pogostemon cablin, 60-100 parts of perilla leaf and 60-100 parts of honey-fried licorice root.

138.9 parts of rhizoma paridis, 83.3 parts of radix scutellariae, 138.9 parts of thunberg fritillary bulb, 277.8 parts of dayflower, 83.3 parts of rhizoma anemarrhenae, 185.2 parts of gypsum, 83.3 parts of dried orange peel, 83.3 parts of fructus aurantii, 138.9 parts of cocklebur fruit, 83.3 parts of bitter almond, 83.3 parts of platycodon grandiflorum, 83.3 parts of pogostemon cablin, 83.3 parts of perilla leaf and 83.3 parts of honey-fried licorice root.

Preferably, the traditional Chinese medicine composition is used for preparing a medicine for treating acute lung injury, and conventional auxiliary materials are added into the traditional Chinese medicine composition according to a conventional process to prepare a clinically acceptable preparation.

Further preferably, the above traditional Chinese medicine composition is used for preparing a medicament for treating acute lung injury, and the clinically acceptable preparation is selected from tablets, capsules, powder, mixtures, pills, granules, syrups, emplastrums, suppositories, aerosols, ointments or injections;

the conventional auxiliary materials are as follows: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, bases, and the like. The filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.; the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, cross-linked sodium carboxymethyl cellulose, etc.; the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like; the adhesive comprises starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.; the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, and the like; the flavoring agent comprises: sweeteners and various essences; the preservative comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroacetidine acetate, eucalyptus oil, etc.; the matrix comprises: PEG6000, PEG4000, insect wax, etc.

The clinically acceptable dosage forms include liquid dosage forms, solid dosage forms, semisolid dosage forms and gas dosage forms. The liquid dosage form comprises: aromatic water, solution, injection, mixture, lotion, liniment, etc. The solid dosage forms include powder, pill, tablet, pellicle, capsule, granule, etc. The semi-solid dosage form comprises: ointments, pastes, gels, and the like. The gaseous formulation comprises: aerosols, sprays, and the like.

Preferably, the clinically acceptable formulation is a granule.

Preferably, the application of the traditional Chinese medicine composition in preparing a medicine for treating acute lung injury comprises the following steps:

decocting the selected weight parts of the scutellaria baicalensis with water, and filtering to obtain first decoction dregs and first filtrate; standing and filtering the first filtrate, and taking filter residue as a crude baicalin product for later use;

adding water into selected parts by weight of dried orange peel, bitter orange, bitter apricot seed, cablin potchouli herb and bupleurum leaf for distillation to obtain distillate and second medicine residue, collecting the distillate, and separating volatile oil for later use;

decocting the first residue and the second residue with selected weight parts of Bulbus Fritillariae Thunbergii, rhizoma paridis, herba Commelinae, rhizoma anemarrhenae, Gypsum Fibrosum, fructus Xanthii, radix Platycodi and Glycyrrhrizae radix in water, and filtering to obtain second filtrate;

concentrating the second filtrate, precipitating with ethanol, filtering to obtain supernatant, recovering ethanol, concentrating to obtain thick extract, adding the crude baicalin, mixing, granulating, drying, spraying the volatile oil, and grading.

Further preferably, the application of the above traditional Chinese medicine composition in preparing a medicament for treating acute lung injury, the step of placing and filtering the first filtrate comprises: adjusting the pH of the first filtrate to 1-2 at 80 deg.C, and standing for filtration.

Preferably, the traditional Chinese medicine composition is used for preparing a medicine for treating acute lung injury, the gypsum is gypsum, the fructus xanthil is fried fructus xanthil, the scutellaria baicalensis is fried scutellaria baicalensis, and the fructus aurantii is bran-fried fructus aurantii.

The technical scheme of the invention has the following advantages:

the invention discovers, through research, the traditional Chinese medicine composition comprises the following raw material medicines: the Chinese medicinal composition prepared from the raw material medicaments can improve the pathological change of acute lung injury diseases induced by LPS, relieve inflammatory reaction, has an obvious treatment effect on the acute lung injury, has an effect superior to that of lung cough, and has a good clinical application prospect.

Furthermore, the invention provides the weight parts of the raw materials in the traditional Chinese medicine composition, and the raw materials in the traditional Chinese medicine composition are matched and act together under a specific proportion, so that the traditional Chinese medicine composition has a treatment effect on acute lung injury.

Furthermore, the invention provides a preparation method of the traditional Chinese medicine composition, which can fully extract the effective medicinal ingredients of the raw materials of the traditional Chinese medicine, so that the prepared medicinal granules can keep high medicinal activity and fully play a role in treating acute lung injury.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.

FIG. 1 is a graph showing the body weight change of rats in each group during the experiment in Experimental example 1 of the present invention;

FIG. 2 is a pathological observation result of lung tissues of rats in each group in Experimental example 1 of the present invention.

Detailed Description

The technical solutions of the present invention will be described clearly and completely below, and it should be apparent that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. In addition, the technical features involved in the different embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.

Example 1

The embodiment provides a traditional Chinese medicine composition, which comprises the following raw material medicines: 138.9g of rhizoma paridis, 83.3g of radix scutellariae, 138.9g of thunberg fritillary bulb, 277.8g of dayflower, 83.3g of rhizoma anemarrhenae, 185.2g of gypsum, 83.3g of dried orange peel, 83.3g of fructus aurantii, 138.9g of cocklebur fruit, 83.3g of bitter apricot kernel, 83.3g of platycodon grandiflorum, 83.3g of pogostemon cablin, 83.3g of perilla leaf and 83.3g of honey-fried licorice root.

The preparation method of the pharmaceutical composition comprises the following steps:

decocting Scutellariae radix with 10 times of water for 1.5 hr, filtering to obtain first residue and first filtrate, concentrating the first filtrate to 5 times, adjusting pH to 1-2 at 80 deg.C, standing for 24 hr, filtering, and collecting residue as baicalin crude product;

wetting 5 medicinal materials of pericarpium citri reticulatae, fructus aurantii, bitter apricot seed, cablin potchouli herb and perilla leaf by weight with water, introducing water vapor for distillation for 3 hours to obtain distillate and second medicine residue, collecting the distillate, and separating volatile oil for later use;

decocting the first residue and the second residue with 8 kinds of medicinal materials including Bulbus Fritillariae Thunbergii, rhizoma paridis, herba Commelinae, rhizoma anemarrhenae, Gypsum Fibrosum, fructus Xanthii, radix Platycodi and Glycyrrhrizae radix with 10 times of water for 2 times (each for 1.5 hr), filtering, and mixing filtrates to obtain a second filtrate;

concentrating the second filtrate (d is 1.15-1.20, measured thermally), adding ethanol to make ethanol content reach 60%, precipitating for 10-12 hr, filtering to obtain supernatant, recovering ethanol under reduced pressure, concentrating to obtain thick extract (d is 1.20-1.25, measured thermally), adding 1.5 times of dextrin and 3.5 times of sucrose into the extract, adding the above baicalin crude product, mixing, granulating, drying, spraying volatile oil, sealing overnight, grading, and packaging.

Example 2

The embodiment provides a traditional Chinese medicine composition, which comprises the following raw material medicines: 160g of rhizoma paridis, 100g of scutellaria baicalensis, 160g of thunberg fritillary bulb, 300g of dayflower, 60g of rhizoma anemarrhenae, 150g of gypsum, 100g of dried orange peel, 100g of fructus aurantii, 150g of cocklebur fruit, 60g of bitter apricot seed, 60g of platycodon grandiflorum, 60g of pogostemon cablin, 60g of perilla leaf and 60g of honey-fried licorice root.

Example 3

The embodiment provides a traditional Chinese medicine composition, which comprises the following raw material medicines: 100g of rhizoma paridis, 60g of scutellaria baicalensis, 100g of thunberg fritillary bulb, 250g of dayflower, 100g of rhizoma anemarrhenae, 200g of gypsum, 70g of dried orange peel, 60g of fructus aurantii, 100g of cocklebur fruit, 100g of bitter apricot seed, 100g of platycodon grandiflorum, 100g of pogostemon cablin, 100g of perilla leaf and 100g of honey-fried licorice root.

Experimental example 1

1. Purpose of the experiment: the effect of the traditional Chinese medicine composition on the treatment of acute lung injury was studied, and the traditional Chinese medicine composition was the medicine granules prepared in example 1.

2. The experimental method comprises the following steps:

2.1 the basis for the selection of the dose to be administered

The equivalent dose between human and animal is converted according to the method described in traditional Chinese medicine pharmacology experimental methodology, the calculation formula is that the equivalent dose of animal (g/kg) is the total daily dose (g) of human/60 kg × (human conversion factor/animal conversion factor), the equivalent dose of rat is calculated according to the clinical dose of drug particles, the equivalent dose is set as middle dose, × 1/2 times of equivalent dose is low dose, and × 2 times of equivalent dose is high dose.

2.2 grounds for the establishment of dosing time

The administration time of the formal test is established according to the literature report and the result of the preliminary test.

2.3 grouping and administration

Rats (SPF grade SD rats, 96 total) were divided into 6 groups, which were: normal group (group a), acute lung injury model group (group B), cough with lung force (group C), drug particle low dose group (group D), drug particle medium dose group (group E), and drug particle high dose group (group F), each group containing 16 drugs. The lung-power cough mixture of the positive control group is 6ml/kg, the high, medium and low dose groups of the drug granules are respectively irrigated with 7.2, 3.6 and 1.8g/kg of drug granule suspension, and the normal control group and the model group are irrigated with the same amount of normal saline. 1 times per day for 7 consecutive days.

2.4 Molding

After 12h of the last administration, LPS 8mg/kg was administered to each of the groups except the normal group, and an equivalent amount of physiological saline was administered to the normal group.

2.5 general observations of animals

The general condition of the rats was recorded during the course of the experiment, while the body weight was weighed every 2 days and recorded.

2.6 Collection of samples

After the intervention of LPS, rats are anesthetized by abdominal aorta, blood is collected, the rat is centrifuged for 10min at 3000r/min in a centrifuge, supernatant is sucked and subpackaged, and the rat is frozen and stored in a refrigerator at the temperature of minus 20 ℃ to be tested.

8 of the rats were taken, the lungs were removed by thoracotomy, the external pulmonary bronchi and adipose tissues were carefully excised, and weighed.

Taking another 8 rats, cutting open the neck skin of the rat, isolating the air outlet pipe in a blunt manner, inserting an indwelling tube into the T-shaped incision, fixing and ligating the right main bronchus, repeatedly pumping and irrigating the left lung for 10 times by using a syringe to obtain 5ml of physiological saline, collecting all BALF, centrifuging (3000 r/min) for 10min, sucking supernatant, subpackaging, and freezing and storing in a refrigerator at the temperature of-20 ℃ to be tested.

Rapidly cutting the thoracic cavity of a rat, and observing the appearance of the whole lung, the secretion of mucus in the bronchus, the bronchus and the alveolar cavity and the like; the right lung lobe is removed by ophthalmic scissors, and is put into 4 percent paraformaldehyde fixing solution for fixing and storing until HE staining is carried out, and the pathological change of lung tissues is observed.

2.7 pulmonary factor and pulmonary Water content determination

Opening chest to take out lung, carefully cutting off external lung trachea and adipose tissue, weighing with lung coefficient of × 100% lung weight/body weight, weighing wet weight, baking in oven to constant weight, weighing dry weight, and calculating lung water content (wet weight-dry weight)/wet weight of × 100%.

2.8 measurement of BALF protein content and Lung Ventilation index

And (3) determining by using a BCA protein quantitative kit, detecting the absorbance of the blood by using a multifunctional enzyme-linked immunosorbent assay at 562nm, drawing a protein standard curve, calculating the protein content in blood plasma and BALF according to the absorbance value, and further calculating the lung permeability index (the lung permeability index is BALF protein content/blood plasma protein content).

2.9 determination of inflammatory cytokines

Changes of expression levels of BALF, IL-17, IL-4, IL-5, IFN-gamma and the like in serum are respectively detected by an ELISA method according to the instruction of a kit.

2.10 Observation of pathological changes in Lung tissue

The fixed lung tissue was taken out, dehydrated with alcohol, embedded in paraffin, and prepared into a tissue-containing wax block, and then sectioned (thickness about 5 μm), stained with HE, pathological changes of the lung tissue were observed with a microscope, and pathological scoring of lung injury and neutrophil count (PMN) were performed.

2.11 statistical analysis

The test data is expressed by mean +/-standard deviation (x +/-S), SPSS 20.0 statistical software is adopted to carry out one-factor variance analysis, and LSD test is adopted when the groups are relatively in accordance with normal distribution and the variances are uniform; if the variance is irregular, a Games-Howell test is adopted. If the normal distribution is not met, then a nonparametric test (Kruskal-Wallis test) is used. Differences of P <0.05 were statistically significant.

3. The experimental results are as follows:

3.1 Experimental groups

No significant change was observed in the rats in each group during the experiment, and the body weight is shown in FIG. 1. The body weights of the normal group (group a), the model group (group B), the cough with lung power (group C), the drug particle low dose group (group D), the drug particle medium dose group (group E), and the drug particle high dose group (group F) increased with time.

3.2 determination of Lung coefficient, Lung Water content and Lung Permeability index

Compared with the normal group (group A), the lung water content and the lung permeability index of the model group (group B) are obviously increased (P is less than 0.01); compared with the model group (group B), the lung water content and the lung permeability index of each administration group are obviously reduced (P is less than 0.01), and the table 1 shows.

TABLE 1 comparison of Lung coefficient, Lung Water content and Lung permeation index for various groups of rats

Group of	Coefficient of lung	Water content of lung	Index of lung permeability
				Group A	1.2±0.03	37.15±1.73	0.072±0.03
Group B	1.2±0.01	58.73±1.12##	0.339±0.06##
				Group C	1.2±0.03	37.70±2.01**	0.188±0.01**
Group D	1.2±0.03	38.91±1.20**	0.194±0.03**
				Group E	1.2±0.02	37.81±1.13**	0.189±0.05**
Group F	1.2±0.01	37.48±1.72**	0.187±0.06**

Note: in comparison to normal group (group a), # P < 0.01; p <0.01 compared to model group (group B).

3.3 determination of inflammatory cytokines

The IL-4, IL-5, IL-17 and IFN-y content of the BALF of each group of rats is shown in Table 2. Compared with the normal group (group A), the serum of the model group (group B) has obviously increased IL-4, IL-5, IL-17 and IFN-gamma, and the difference has statistical significance (P is less than 0.01); compared with the model group (B group), IL-4, IL-5, IL-17 and IFN-gamma are all reduced in each administration group, wherein IL-4, IL-17 and IFN-gamma are significantly reduced (P <0.05 or P < 0.01).

TABLE 2 comparison of IL-4, IL-5, IL-17 and IFN-. gamma.content in BALF of rats in each group

Note: in comparison to normal group (group a), # P < 0.01; p <0.05, P <0.01 compared to model group (group B).

The contents of IL-l β, IL-4, IL-5, IL-17, IFN-gamma and TNF- α in the sera of rats in each group are shown in Table 3. compared with the normal group (group A), the contents of IL-l β, IL-4, IL-5, IL-17, IFN-gamma and TNF- α in the sera of model group (group B) are obviously increased, and the difference has statistical significance (P <0.01), and compared with the model group (group B), the contents of IL-l β, IL-4, IL-5, IL-17, IFN-gamma and TNF- α in each administration group are all reduced.

TABLE 3 serum IL-l β, IL-4, IL-5, IL-6, IL-10, IL-17, IFN-. gamma.and TNF- α levels in groups of rats

pg/ml

Group A

Group B

Group C

Group D

Group E

Group F

IL-lβ

57.76±14.65

320.64±43.72^##

265.45±32.21^*

267.52±20.02^*

249.93±21.75^*

224.94±56.76^**

IL-4

57.64±3.28

136.62±46.33^##

73.00±27.99^*

85.84±38.60

72.48±35.11^*

63.85±21.14^**

IL-5

75.33±29.65

248.62±59.87^##

241.17±26.69

248.42±22.26

238.80±54.39

235.68±26.37^*

IL-17

300.54±47.35

760.52±52.60^##

398.75±51.63^**

430.17±167.11

383.12±57.70^**

315.54±40.90^**

IFN-γ

238.11±52.42

321.66±60.59^##

275.16±22.62^*

284.97±37.87^*

275.80±59.70^*

275.52±47.78^*

TNF-α

450.40±184.09

1156.34±362.94^##

910.40±368.19

926.58±336.94

818.38±286.45^*

724.24±343.60^**

Note: compared to the normal group (group a), # P <0.05, # P < 0.01; p <0.05, P <0.01 compared to model group (group B).

3.4 histological observation of lung tissue pathology

The general observation of lung tissues shows that the lung tissues of the rats in the normal group have smooth surfaces, red color and no congestion or bleeding; the surface of the lung tissue of the rat in the model group is provided with a dark red congestion area with irregular shape; the congestion phenomenon after the medicine intervention is improved.

After HE staining of lung tissue of rats in each group, the results of observation by an optical microscope were as follows: the normal group has no obvious inflammatory reaction, the lung tissue structure is complete, and no inflammatory cell infiltration exists; the model group shows that congestion occurs in bronchus and periphery, alveolar wall is thickened, alveolar cavity is reduced, inflammatory cells such as a large number of eosinophilic granulocytes, lymphocytes and the like infiltrate in the alveolar cavity, the space and the periphery of blood vessels, and the basement membrane of the trachea is occasionally cracked; compared with the model group, the congestion phenomenon, alveolar wall thickness, infiltration of inflammatory cells such as eosinophils and lymphocytes in the drug intervention group are all reduced compared with the model group, and the figure 2 shows that the drug intervention group has the advantages of reducing the congestion phenomenon, the alveolar wall thickness, the infiltration of inflammatory cells such as eosinophils and lymphocytes and the like.

It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims

1. The application of a traditional Chinese medicine composition in preparing a medicine for treating acute lung injury is characterized in that the traditional Chinese medicine composition comprises the following raw material medicines: rhizoma paridis, scutellaria baicalensis, thunberg fritillary bulb, dayflower, rhizoma anemarrhenae, gypsum, pericarpium citri reticulatae, fructus aurantii, cocklebur fruit, bitter almond, platycodon grandiflorum, pogostemon cablin, perilla leaf and honey-fried licorice root.

2. The application of the traditional Chinese medicine composition according to claim 1 in preparing a medicine for treating acute lung injury is characterized by comprising the following raw material medicines in parts by weight:

3. The use of the traditional Chinese medicine composition according to claim 1 or 2 in the preparation of a medicament for treating acute lung injury is characterized by comprising the following raw material medicines in parts by weight:

4. The use of the traditional Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a medicament for treating acute lung injury, wherein the traditional Chinese medicine composition is prepared into a clinically acceptable preparation by adding conventional auxiliary materials according to a conventional process.

5. The use of the Chinese medicinal composition according to claim 4, in the preparation of a medicament for treating acute lung injury, wherein the clinically acceptable formulation is selected from tablets, capsules, powders, mixtures, pills, granules, syrups, patches, suppositories, aerosols, ointments or injections;

preferably, the clinically acceptable formulation is a granule.

6. The use of the Chinese medicinal composition according to any one of claims 1 to 5 in the preparation of a medicament for the treatment of acute lung injury, wherein the preparation method of the Chinese medicinal composition comprises the following steps:

7. The use of the Chinese medicinal composition of claim 6 in the preparation of a medicament for treating acute lung injury, wherein the step of standing and filtering the first filtrate comprises: adjusting the pH of the first filtrate to 1-2 at 80 deg.C, and standing for filtration.

8. The use of a Chinese medicinal composition according to any one of claims 1-7 in the preparation of a medicament for the treatment of acute lung injury, wherein the gypsum is gypsum, the fructus Xanthii is parched fructus Xanthii, the Scutellariae radix is parched Scutellariae radix, and the fructus Aurantii is bran-parched fructus Aurantii.